drugset / Trial / NCT00347971
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).
Timeline
- Start
- 2006-06
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Interleukin-21 | Protein / enzyme biologic | 30 ug/kg | Intravenous |
| Subject | Recombinant Human Interleukin-21 | Protein / enzyme biologic | 100 ug/kg | Intravenous |
| Subject | Recombinant Human Interleukin-21 | Protein / enzyme biologic | 150 ug/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |